U.S.-Israel Tussle Over IP Rights Continues; New Free Trade Policy Is Limited
Executive Summary
The generic pharmaceutical industry won a victory when the United States agreed to loosen intellectual property restrictions in its free trade agreements. But the policy does not apply to every trading partner and some countries continue to battle against terms they say will delay the marketing of low-cost drugs
You may also be interested in...
Global IP Protection: Data Exclusivity Is Top USTR Concern As Licensing Recedes
The U.S. Trade Representative's most recent report on global intellectual property rights suggests compulsory licensing may be receding somewhat as a worry for pharmaceutical companies, but inadequate data protection remains a strong concern
Global IP Protection: Data Exclusivity Is Top USTR Concern As Licensing Recedes
The U.S. Trade Representative's most recent report on global intellectual property rights suggests compulsory licensing may be receding somewhat as a worry for pharmaceutical companies, but inadequate data protection remains a strong concern
Global IP Protection: U.S. “Priority Watch List” Includes Major Suppliers
The U.S. Trade Representative's 2009 Special 301 Report cites a number of countries that serve as major suppliers of pharmaceuticals for failing to provide adequate protection of intellectual property rights